Bergen, June 19, 2013 – BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
“The Phase 1 clinical trial of BGB324 will provide the opportunity to demonstrate the safety of BGB324 and evaluate clinical biomarker and pharmacodynamic assays the company has also developed.” stated Richard Godfrey, CEO of BerGenBio. “Our extensive preclinical data suggest that BGB324 has wide therapeutic potential to address a range of clinically challenging cancers and the growing problem of acquired drug-resistance”.
About BerGenBio AS
BerGenBio AS is a biopharmaceutical company located in Bergen, Norway. The company is committed to developing first in class therapeutics that inhibit EMT, preventing the formation of cancer stem cells and disrupting the important mechanisms of acquired cancer drug resistance. The company is founded on proprietary platform technology called CellSelect™, which uses information from RNAi screening studies to identify and validate novel drug targets and biomarkers. BGB324 is the first compound in BerGenBio’s pipeline to enter clinical trials, with additional compounds and drug targets at different stages of preclinical development.
Richard Godfrey, CEO
Tel +47 917 86 304
Media: Richard Hayhurst, Richard Hayhurst Associates
Tel + +44 (0) 7711 821527